Kymera Therapeutics, Inc. (KYMR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KYMR currently has 82.3M outstanding shares. with limited dilution risk as only 12M additional shares (14.5%) are authorized for issuance. The company has significantly diluted shareholders by 31.74% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 30, 2026 |
10-Q filing | 82.3M shares outstanding |
82M | 12M |
| May 09, 2025 |
10-Q filing | 65.1M shares outstanding |
65M | 12M |
| Feb 27, 2025 |
10-K filing | 64.9M shares outstanding |
65M | 12M |
| Oct 31, 2024 |
10-Q filing | 64.8M shares outstanding |
65M | 12M |
| Aug 07, 2024 |
10-Q filing | 61.8M shares outstanding |
62M | 12M |
| May 02, 2024 |
10-Q filing | 61.4M shares outstanding |
61M | 12M |
| Feb 22, 2024 |
10-K filing | 58.4M shares outstanding |
58M | 12M |
| Nov 02, 2023 |
10-Q filing | 58.4M shares outstanding |
58M | 12M |
| Aug 03, 2023 |
10-Q filing | 58.3M shares outstanding |
58M | 12M |
| May 04, 2023 |
10-Q filing | 58.2M shares outstanding |
58M | 12M |
| Feb 23, 2023 |
10-K filing | 53.9M shares outstanding |
54M | 12M |
| Nov 03, 2022 |
10-Q filing | 54.5M shares outstanding |
55M | 12M |
| Aug 09, 2022 |
10-Q filing | 51.8M shares outstanding |
52M | 12M |
| May 03, 2022 |
10-Q filing | 51.7M shares outstanding |
52M | 12M |
| Feb 24, 2022 |
10-K filing | 51.7M shares outstanding |
52M | 12M |
| Nov 10, 2021 |
10-Q filing | 51.4M shares outstanding |
51M | 12M |
| Aug 06, 2021 |
10-Q filing | 51.0M shares outstanding |
51M | 12M |
| Jun 28, 2021 |
S-1 filing: This is an S-1 filing for an offering of common stock with an option for underwriters to purchase additional shares, intended to fund research and development of degrader medicines. |
45M | 12M |
| May 06, 2021 |
10-Q filing | 45.0M shares outstanding |
45M | 7.4M |
| Mar 11, 2021 |
10-K filing | 44.8M shares outstanding |
45M | 7.4M |
| Nov 05, 2020 |
10-Q filing | 44.5M shares outstanding |
44M | 7.4M |
| Aug 17, 2020 |
S-1/A filing: Kymera Therapeutics, Inc. is offering 7,360,000 shares of common stock in its initial public offering, with an expected price between $16.00 and $18.00 per share. |
N/A | 7.4M |
| Aug 13, 2020 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. |
N/A | 0 |
| Aug 05, 2020 |
S-1/A filing: This is an S-1/A filing including information on recent sales of unregistered securities, including issuances of capital stock and grants/exercises of stock options. |
N/A | 0 |
| Jul 31, 2020 |
S-1 filing: The filing is an S-1 form for an initial public offering of common stock. |
N/A | 0 |